Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of listeria-based vaccine with anti-OX40 or anti-GITR antibodies

A listeria and antibody technology, applied in the direction of antibodies, drug combinations, bacterial antigen components, etc., can solve toxicity and other problems

Inactive Publication Date: 2017-09-26
ADVAXIS +1
View PDF24 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, the use of such agonist antibodies can lead to toxicity issues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of listeria-based vaccine with anti-OX40 or anti-GITR antibodies
  • Combination of listeria-based vaccine with anti-OX40 or anti-GITR antibodies
  • Combination of listeria-based vaccine with anti-OX40 or anti-GITR antibodies

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0297] Methods of making these fragments are known in the art. (See, eg, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, which is incorporated herein by reference).

[0298] In some embodiments, antibody fragments can be prepared by proteolysis of antibodies or by expression of DNA encoding the fragments in E. coli or mammalian cells (eg, Chinese hamster egg cell culture or other protein expression systems).

[0299] In some embodiments, antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be obtained as F(ab') by enzymatic cleavage of antibodies with pepsin. 2 The indicated 5S fragment was prepared. This fragment can be further cleaved using a thiol reducing agent, and optionally a capping group using a thiol group obtained from cleavage of the disulfide bond, to generate a 3.5S Fab' monovalent fragment. Alternatively, enzymatic clea...

example 1-2

[0368] cell line

[0369] C57BL / 6 syngeneic TC-1 tumors were immortalized with HPV-16 E6 and E7 and transformed with the c-Ha-ras oncogene. TC-1 provided by T.C. Wu (Johns Hopkins University School of Medicine, Baltimore, MD) are highly tumorigenic lung epithelial cells that express low levels of HPV-16 E6 and E7 and are transformed by the c-Ha-ras oncogene . Keep TC-1 at 37°C and 10% CO 2 Grow in RPMI 1640, 10% FCS, 2mM L-glutamine, 100U / ml penicillin, 100μg / ml streptomycin, 100μM non-essential amino acids, 1mM sodium pyruvate, 50 micromolar (mcM) 2-ME, 400 Micrograms (mcg) / mlG418 and 10% National Collection Type Culture-109 medium (National Collection Type Culture-109 medium). C3 are mouse embryonic cells from C57BL / 6 mice immortalized with the complete HPV 16 genome and transformed with pEJ-ras. EL-4 / E7 is thymoma EL-4 transduced with E7 retrovirus.

[0370] Listeria monocytogenes strains and reproduction

[0371] The Listeria strain used was Lm-LLO-E7, also referred to...

example 1

[0388] Example 1: LLO-antigen fusions induce anti-tumor immunity

[0389] result

[0390] The ability of Lm-E7 and Lm-LLO-E7 to affect the growth of TC-1 was compared. Subcutaneous tumors were established on the left flank of C57BL / 6 mice. Seven days later, the tumor had reached a palpable size (4-5mm). On days 7 and 14, mice were inoculated with 0.1 LD 50 Lm-E7, Lm-LLO-E7 or Lm-Gag and Lm-LLO-NP as controls. Lm-LLO-E7 induced complete regression of 75% of established TC-1 tumors, while tumor growth was controlled in the other 2 mice in the group ( image 3 ). In contrast, immunization with Lm-E7 and Lm-Gag did not induce tumor regression. The experiment was repeated several times, always with very similar results. In addition, Lm-LLO-E7 also obtained similar results under different immunization schemes. In another experiment, a single immunization was able to cure established 5 mm TC-1 tumors in mice.

[0391] In other experiments, similar results were obtained with ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

Disclosed herein are compositions comprising use of compositions comprising a live attenuated recombinant Listeria strain comprising a fusion protein of a truncated listeriolysin O (LLO) protein, a truncated ActA protein, or a PEST amino acid sequence fused to a heterologous antigen, including a tumor-associated antigen, wherein the compositions further comprise or are co-administered with an antibody or fragment thereof. Also disclosed are combination therapies comprising use of these compositions comprising live attenuated recombiant Listeria strains, in conjuction with an antibody or fragment thereof for use in treating, protecting against, and / or inducing an immune response against a tumor, especially wherein the treating, protection against and / or inducing an immune response increases percent survival in a subject.

Description

technical field [0001] Disclosed herein are compositions, including the use of compositions comprising a live attenuated recombinant Listeria strain comprising a truncated Listerialysin fused to a heterologous antigen O(LLO) protein, truncated ActA protein or fusion protein of PEST amino acid sequence, said heterologous antigen includes tumor-associated antigen, wherein said composition further comprises or is co-administered with antibody or its fragment. Also disclosed are combination therapies for the treatment, defense and / or induction of an immune response against tumors comprising the use of these compositions comprising live attenuated recombinant Listeria strains in combination with antibodies or fragments thereof, in particular is the percentage of survival of subjects wherein the treating, defending and / or inducing an immune response increases the survival of the subjects. Background technique [0002] Listeria monocytogenes (Lm) is a Gram-positive facultative int...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P35/00C07K14/025C07K14/195C07K16/28
CPCA61K39/0011C07K14/025C07K14/195C07K16/2818A61K39/00A61K39/02A61K39/39C07K14/47C07K14/705A61K2039/522A61K2039/505A61K2039/572C07K2319/95C07K2319/40A61K39/001106A61K39/001194A61P13/08A61P15/00A61P31/20A61P35/00A61P37/04A61P43/00C12N2710/20034C07K14/005
Inventor S·卡赫里夫M·马克里提齐安R·珀蒂A·瓦勒查
Owner ADVAXIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com